March 20, 2020 / 2:13 PM / 11 days ago

BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Updates On Impact Of Covid-19 On Co's Business

March 20 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

* EXPECTED REVENUE IN Q1 OF 2020 WILL BE IN RANGE OF RMB18.70 MILLION TO RMB36.50 MILLION

* CORONAVIRUS EPIDEMIC CAUSED SIGNIFICANT DECLINE IN SALES OF GROUP’S THREE MAIN PRODUCTS

* DECLINE IN RESULTS IN Q1 HAS LIMITED IMPACT ON ANNUAL RESULTS OF 2020

* DELIVERY FROM CERTAIN RAW MATERIAL SUPPLIERS DELAYED

* EXPECTED THAT NET LOSS ATTRIBUTABLE IN RANGE OF ABOUT RMB7.34 MILLION TO RMB19.80 MILLION FOR Q1 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below